Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60-0175:: a pharmacological analysis

被引:59
作者
Dekeyne, A [1 ]
Girardon, S [1 ]
Millan, MJ [1 ]
机构
[1] Inst Rech Servier, Dept Psychopharmacol, F-78290 Paris, France
关键词
Ro; 60-0175; drug discrimination; 5-HT2A receptor; 5-HT2C receptor; depression; schizophrenia;
D O I
10.1016/S0028-3908(98)00203-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Employing a Fixed-Ratio 10, food-reinforced protocol, rats were trained to recognize the discriminative stimulus (DS) properties of the novel, potent, 5-HT2C agonist, Ro 60-0175 (2.5 mg/kg, i.p.). This schedule generated appropriate drug versus vehicle responding after 50 +/- 5 training sessions and Ro 60-0175 elicited full (100%) drug selection with an effective dose(50) (ED50) of 0.6 mg/kg, i.p.. The 5-HT2C receptor agonists, mCPP and MK 212, fully generalized to Ro 60-0175 with ED(50)s of 0.8 and 0.4 mg/kg, s.c., respectively, whereas the preferential 5-HT2B agonist, BW 723C86 (>10.0 mg/kg, s.c.) and the 5-HT2A agonist, DOI (> 2.5 mg/kg, s.c.), were ineffective. The 5-HT2A/2B/2C receptor antagonist, mianserin, dose-dependently blocked the DS properties of Ro 60-0175 with an ED50 of 0.7 mg/kg, s.c. This action was mimicked by the novel, 5-HT2B/2C antagonist, SE 206,553 (ED50 = 0.3 mg/kg, s.c.), whereas the selective 5-HT2A antagonist, MDL 100,907 (> 0.63 mg/kg, s.c.), was ineffective. Further, the selective 5-HT2C antagonist, SE 242,084, dose-dependently and fully blocked drug selection (ED50 = 0.2 mg/kg, i.p.), whereas the selective 5-HT2B antagonist, SE 204,741, was not active (> 0.63 mg/kg, i.p.). In conclusion, these data demonstrate that Ro 60-0175 generates a robust DS and suggest that activation of 5-HT50 receptors is the principal mechanism underlying its DS properties. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:415 / 423
页数:9
相关论文
共 62 条
[1]  
Ainsworth K, 1996, BRIT J PHARMACOL, V117, pP178
[2]   5-HT2 RECEPTOR SUBTYPES - A FAMILY RE-UNITED [J].
BAXTER, G ;
KENNETT, G ;
BLANEY, F ;
BLACKBURN, T .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (03) :105-110
[3]   MOLECULAR-BIOLOGY OF 5-HT RECEPTORS [J].
BOESS, FG ;
MARTIN, IL .
NEUROPHARMACOLOGY, 1994, 33 (3-4) :275-317
[4]   Novel agonists of 5HT(2C) receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder [J].
Bos, M ;
Jenck, F ;
Martin, JR ;
Moreau, JL ;
Sleight, AJ ;
Wichmann, J ;
Widmer, U .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (17) :2762-2769
[5]   Pharmacologic evaluation of the discriminative stimulus of metachlorophenylpiperazine [J].
Bourson, A ;
Wanner, D ;
Wyler, R ;
Petit, N ;
Zwingelstein, C ;
Rudler, A ;
Sleight, AJ .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1996, 53 (01) :107-114
[6]  
BRUNELLO N, 1995, NEUROPSYCHOPHARMACOL, V13, P177, DOI 10.1016/0893-133X(95)00068-O
[7]   INVOLVEMENT OF 5-HT2C RECEPTORS IN MEDIATING THE DISCRIMINATIVE STIMULUS PROPERTIES OF M-CHLOROPHENYLPIPERAZINE (MCPP) [J].
CALLAHAN, PM ;
CUNNINGHAM, KA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 257 (1-2) :27-38
[8]   CENTRAL SEROTONIN RECEPTORS - EFFECTOR SYSTEMS, PHYSIOLOGICAL ROLES AND REGULATION [J].
CONN, PJ ;
SANDERSBUSH, E .
PSYCHOPHARMACOLOGY, 1987, 92 (03) :267-277
[9]  
COPLAN JD, 1992, NEUROPSYCHOPHARMACOL, V6, P189
[10]  
DEAKIN JFW, 1994, BRIT ASS PSYCHOPHARM, V13, P87